Senolytics: trials and judgements

(Feb 5, 2019)

In a previous post we considered the advantages of repurposing existing drugs to treat a new condition. The fact such treatments had already undergone safety testing and regulatory approval shortens the usually lengthy journey to the clinic. Such acceleration is particularly welcome during a gold rush. But don't visualise old prospectors sieving sand whilst cackling about them thar hills: in this story the old-timers involved are our senescent cells, and the gold rush is the race to discover senolytic drugs to remove them, potentially ameliorating multiple diseases of aging simultaneously.

Ignoring the major challenge of developing potential treatments, all candidate drugs must eventually undertake…

Read more

Tags: longevity, senescence

Find by key-word


Find by date


Find by tag (show all )